The study aims to identify prescribing and switching patterns of antipsychotics in clinical practice. A 16-month, prospective study was conducted at the Psychiatric Hospital Idrija, Slovenia. Inpatients (N = 311) with schizophrenia spectrum disorders were observed. The causes for switching antipsychotics and switching strategies were analyzed. Analyzing a total of 3954 prescriptions, the collected data confirmed that treatment strategies in this psychiatric hospital are very complex. It was found that 37 percent of inpatients had at least one switch. Moreover, switches that included three or more antipsychotics were detected. The most common causes for switching antipsychotics were adverse reactions and inefficacy or lack of efficacy. Among switching options, abrupt switch was recorded several times. As some patients are receiving several antipsychotics at the same time, it is possible that unusual switching occurs in clinical practice. It seems that the choice of switching strategy is also affected by the cause and urgency for switching an antipsychotic.
1. J. M. Davis and S. Leucht, Commentary on strategies for switching antipsychotics, BMC Med. 6 (2008) 18-18; DOI: 10.1186/1741-7015-6-18.
2. N. H. Covell, C. T. Jackson and E. M. Weissman, Health monitoring for patients who have schizophrenia. Summary of the Mount Sinai conference recommendations, Postgrad. Med., Sept. 2006, Spec. No. 20-26.
3. J. M. Kane, S. Leucht, D. Carpenter and J. P. Docherty, The expert consensus guideline series, optimizing pharmacologic treatment of psychotic disorders, introduction: methods, commentary, and summary, J. Clin. Psychiat. 64 (Suppl. 12) (2003) 5-19.
4. P. J. Weiden, Discontinuation and switching antipsychotic medications: understanding the CATIE schizophrenia trial, J. Clin. Psychiat. 68 (Suppl. 1) (2007) 12-19.
5. R. A. Rosenheck, S. Davis, N. Covell, S. Essock, M. Swartz, S. Stroup, J. McEvoy and J. Lieberman, Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial, Schizophr. Res. 107 (2009) 22-29; DOI: 10.1016/j.schres.2008.09.031.
6. S. Bazire, Psychotropic Drug Directory: The Professional’s Pocket Handbook and Aide Memoire, Health- Comm UK, Aberdeen 2010.
7. P. M. Haddad and A. Wieck, Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management, Drugs 64 (2004) 2291-2314.
8. D. D. Miller, Atypical antipsychotics: sleep, sedation and efficacy, Prim. Care Comp. J. Clin. Psychiat. 6 (2004) 3-7.
9. C. H. Hennekens, A. R. Hennekens, D. Hollar and D. E. Casey, Schizophrenia and increased risks of cardiovascular disease, Am. Heart J. 150 (2005) 1115-1121; DOI: 10.1016/j.ahj.2005.02.007.
10. M. Dossenbach, Y. Dyachkova, S. Pirildar, M. Anders, A. Khalil, A. Araszkiewicz, T. Shakhnovich, A. Akram, J. Pecenak, M. McBride and T. Treuer, Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study, Eur. Psychiat. 21 (2006) 251-258; DOI: 10.1016/j.eurpsy.2005.12.005.
11. J. W. Newcomer and D. W. Haupt, The metabolic effects of antipsychotic medications, Can. J. Psychiat. 51 (2006) 480- 491.
12. S. M. Stahl, Stahl’s Essential Psychopharmacology, Cambridge University Press, Cambridge 2009.
13. J. A. Lieberman, T. S. Stroup, J. P. McEvoy, M. S. Swartz, R. A. Rosenheck, D. O. Perkins, R. S. Keefe, S. M. Davis, B. D. Lebowitz, J. Severe, J. K. Hsiao and clinical antipsychotic trials of intervention effectiveness (CATIE) investigators, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia, N. Engl. J. Med. 353 (2005) 1209-1223; DOI: 10.1056/NEJMoa051688.
14. P. Chue, The relationship between patient satisfaction and treatment outcomes in schizophrenia, J. Psychopharmacol. 20 (Suppl. 6) (2006) 38-56; DOI: 10.1177/1359786806071246.
15. J. M. Haro and L. Salvador-Carulla, The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia, CNS Drugs 20 (2006) 293-301.
16. P. J. Weiden and M. Olfson, Cost of relapse in schizophrenia, Schizophr. Bull. 21 (1995) 419-429.
17. S. H. Preskorn and D. Flockhart, Guide to psychiatric drug interactions, Prim. Psychiat. 16 (2009) 45-74.
18. I. H. Stockley, Stokley’s Drug Interactions, Pharmaceutical Press, London 2002.
19. A. De Nayer, E. Windhager, I. Irmansyah, I. Larmo, B. Lindenbauer, H. Rittmannsberger, T. Platz, A. Jones, J. Whiteford and C. Altman, Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics, Int. J. Psychiat. Clin. Pract. 7 (2003) 59-66; DOI: 10.1080/13651500310001095.
20. P. F. Buckley and C. U. Correll, Strategies for dosing and switching antipsychotics for optimal clinical management, J. Clin. Psychiatry 69 (Suppl. 1) (2008) 4-17.
21. C. U. Correll, Real-life switching strategies with second-generation antipsychotics, J. Clin. Psychiat. 67 (2006) 160-161.
22. S. Ganesan, V. Agambaram, F. Randeree, I. Eggens, K. Huizar, D. Meuliend and on behalf of 147 investigators, Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia, Curr. Med. Res. Opin. 24 (2008) 21-32; DOI: 10.1185/030079908X253384.
23. J. Karagianis, R. Williams, L. Davis, R. Procyshyn, N. Monga, J. Hanley, R. Chandrasena, A. Thakur and R. Dickson, Antipsychotics switching: results from a one-year prospective, observational study of patients with schizophrenia, Curr. Med. Res. Opin. 25 (2009) 2121-2132; DOI: 10.1185/03007990903102966.
24. H. C. Lin, M. Y. Chong, Y. Lee, W. C. Yeh and P. Y. Lin, Switching of antipsychotics to aripiprazole in the treatment of schizophrenia, Chang Gung Med. J. 32 (2009) 409-416.
25. D. Taylor, C. Paton and S. Kapur, The Maudsley Prescribing Guidelines in Psychiatry, Wiley Blackwell, Oxford 2015.
26. A. F. Lehman, J. A. Lieberman, L. B. Dixon, T. H. McGlashan, A. Miller, D. O. Perkins and J. Kreyenbuhl, American Psychiatric Association and Steering Committee on Practice Guidelines, Practice guideline for the treatment of patients with schizophrenia, Am. J. Psychiat. 161 (Suppl. 2) (2004) 1-56.
27. J. Bolcato, G. Terrazzani, P. Giusti, T. Walley and A. Chinellato, Atypical antipsychotic prescribing patterns in an Italian district 2001-2009 and the impact of regulatory warnings, Open Sci. J. Clin. Med. 2 (2014) 10-14; DOI: 10.1016/j.pnpbp.2004.06.017.
28. T. R. Barnes and Schizophrenia Consensus Group of British Association for Psychopharmacology, Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology, J. Psychopharmacol. 25 (2011) 567-620; DOI: 10.1177/0269881110391123.
29. A. Hassan, P. Falkai, T. Wobrock, J. Lieberman, B. Glenthoj, W. F. Gattaz, F. Thibaut, H. J. Möller and World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia, World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance, World J. Biol. Psychiat. 13 (2012) 318-378; DOI: 10.3109/15622975.2012.696143.
30. R. A. Hamilton, L. L. Briceland and M. H. Andritz, Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population, Pharmacotherapy 18 (1998) 1112-1120.
31. C. S. Moura, F. A. Acurcio and N. O. Belo, Drug-drug interactions associated with length of stay and cost of hospitalization, J. Pharm. Pharm. Sci. 12 (2009) 266-272.
32. P. L. Canales, P. G. Dorson and M. L. Crismon, Outcomes assessment of clinical pharmacy services in a psychiatric inpatient setting, Am. J. Health Syst. Pharm. 58 (2001) 1309-1316; DOI: 10.3390/ ijerph111010967.